EIKN

Eikon Therapeutics Inc

7.26

Oct 23 • 3:59 PM ET -0.98 (-11.89%)

7.21

Aftermarket • 7:30 PM ET -0.05 (-0.67%)

Healthcare Biotechnology USA Small NASD

Oct 23, 9:50 AMEikon Therapeutics reports encouraging Phase 1/2 safety and antitumor activity data at ESMO for PARP1 and WRN inhibitors in advanced solid tumors

Peers: IDYA REPL TNGX IMCR IOVA AZN ORIC ARVN RCUS MRK

| Held by: IWM VTI VXF IWO VTWO SCHA IWC IWN SBIO OMFS

Scroll to Statements

Index	RUT
Market Cap	393.24M
Enterprise Value	113.88M
Income	-
Sales	-
Book/sh	8.62
Cash/sh	9.81
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	-
IPO	Feb 05, 2026

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	0.84
P/C	0.74
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	9.89
Current Ratio	9.89
Debt/Eq	0.54
LT Debt/Eq	0.52
Option/Short	No / Yes

EPS (ttm)	-
EPS next Y	-7.28
EPS next Q	-1.70
EPS this Y	93.82%
EPS next Y	-2.23%
EPS next 5Y	62.89%
EPS past 3/5Y	-13.35% -
Sales past 3/5Y	- -
EPS Y/Y TTM	-
Sales Y/Y TTM	-
EPS Q/Q	-10.51%
Sales Q/Q	-
Earnings	Aug 13 AMC
EPS/Sales Surpr.	-2.84% -

Insider Own	53.39%
Insider Trans	0.31%
Inst Own	40.91%
Inst Trans	1.09%
ROA	-
ROE	-
ROIC	-
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	-4.15%
SMA50	-20.78%
SMA200	-31.30%
Trades

Shs Outstand	54.15M
Shs Float	25.25M
Short Float	24.93%
Short Ratio	12.06
Short Interest	6.29M
52W High	17.40 -58.28%
52W Low	6.45 12.59%
Volatility	9.55% 7.95%
ATR (14)	0.67
RSI (14)	41.10
Beta	-
Rel Volume	0.61
Avg Volume	521.88K
Volume	318,457

Perf Week	-2.16%
Perf Month	-12.42%
Perf Quarter	-26.52%
Perf Half Y	-24.81%
Perf YTD	-57.42%
Perf Year	-
Perf 3Y	-
Perf 5Y	-
Perf 10Y	-
Recom	1.57
Target Price	24.33
Prev Close	8.24
Price	7.26
Change %	-11.89%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-16-26	Initiated	H.C. Wainwright	Buy	$23
Mar-02-26	Initiated	Morgan Stanley	Overweight	$32
Mar-02-26	Initiated	Mizuho	Outperform	$26
Mar-02-26	Initiated	JP Morgan	Overweight	$29
Mar-02-26	Initiated	Cantor Fitzgerald	Overweight
Mar-02-26	Initiated	BofA Securities	Buy	$34
Feb-26-26	Initiated	Wedbush	Underperform	$7

Oct-23-26 09:15AM	Eikon Therapeutics Presents Data from PARP1-Selective and WRN Helicase Programs at the European Society for Medical Oncology Congress (GlobeNewswire) -11.89%
Oct-18-26 06:05PM	Eikon Therapeutics Announces Availability of Seven Abstracts for Presentation at the European Society for Medical Oncology Congress (GlobeNewswire)
Oct-15-26 08:00AM	Eikon Therapeutics Submits IND for Novel Androgen Receptor Antagonist EIK1006 in Prostate Cancer (GlobeNewswire) +7.56%
Sep-03-26 07:30AM	Eikon Therapeutics Appoints Ching-Pin Chang, M.D., Ph.D. as Executive Vice President and Chief Scientific Officer (GlobeNewswire)
Aug-26-26 07:30AM	Eikon Therapeutics to Participate in Investor Conferences in September 2026 (GlobeNewswire)
04:15PM	Loading…
Aug-18-26 04:15PM	Eikon Therapeutics to Participate in KOL Event on Therapeutic Use of PARP Inhibitors in Oncology Hosted by Cantor Fitzgerald (GlobeNewswire) +11.27%
Aug-13-26 04:02PM	Eikon Therapeutics Reports Second Quarter 2026 Financial Results and Provides Clinical Updates (GlobeNewswire) +6.97%
Aug-11-26 07:30AM	Eikon Therapeutics Announces Dose Selection for TeLuRide-006, an Ongoing Adaptive Phase 2/3 Trial of EIK1001 in Advanced Melanoma (GlobeNewswire) +5.14%
Aug-10-26 07:30AM	Eikon Therapeutics Appoints Johnny Bennett, Ph.D. to its Scientific Advisory Board (GlobeNewswire)
Jul-27-26 07:30AM	Eikon Therapeutics Announces First Patient Dosed in TeLuRide-008, a Registrational Phase 2/3 Trial of EIK1001 in Non-Small Cell Lung Cancer (GlobeNewswire) +11.01%
Jul-20-26 08:00AM	Eikon Therapeutics Announces Seven Abstracts Accepted for Presentation at the 2026 European Society of Medical Oncology (ESMO) Congress (GlobeNewswire)
Jun-25-26 04:15PM	Eikon Therapeutics to Join the Russell 3000 Index (GlobeNewswire) +16.24%
Jun-08-26 08:00AM	Eikon Therapeutics Announces the Appointment of Ma. Fatima D. Francisco to its Board of Directors (GlobeNewswire)
May-30-26 02:30PM	Eikon Therapeutics Presents Data on Clinical-Stage Programs at the 2026 Annual Meeting of the American Society of Clinical Oncology (GlobeNewswire)
May-21-26 05:05PM	Eikon Therapeutics Announces Availability of Six Abstracts for Presentation at the 2026 Annual Meeting of the American Society of Clinical Oncology (GlobeNewswire)
04:01PM	Loading…
May-11-26 04:01PM	Eikon Therapeutics Reports First Quarter 2026 Financial Results and Provides Clinical Updates (GlobeNewswire) +15.88%
Mar-30-26 07:48AM	Eikon Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Provides Clinical and Corporate Updates (GlobeNewswire)
Feb-26-26 09:42AM	Spotify upgraded, First Solar downgraded: Wall Street's top analyst calls (The Fly) -8.39%
Feb-24-26 12:02PM	Medtronic Diabetes Unit MiniMed Seeks $784 Million in US IPO (Bloomberg)
Feb-09-26 08:30AM	Wall Street Braces For IPO Boom: Goldman Says 2026 Listings Could Hit $160 Billion As Tech, AI Lead (Benzinga)
Feb-06-26 04:18PM	Jennifer Garner's Once Upon a Farm Rises Nearly 20% To Wrap Up Busy Week for IPOs (Barrons.com)
Feb-05-26 07:23PM	This Mobile App Marketing Firm Is Holding Off an IPO for Now (Barrons.com)
Feb-04-26 07:59PM	Eikon Therapeutics Announces Pricing of Upsized Initial Public Offering (GlobeNewswire)

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Column Group IV GP, LP	10% Owner	Sep 03 '26	Buy	11.56	89,200	1,031,045	89,200	Sep 08 04:33 PM
Column Group IV GP, LP	10% Owner	Feb 06 '26	Buy	18.00	2,117,760	38,119,680	4,312,139	Feb 09 09:19 PM
Foresite Capital Management IV	10% Owner	Feb 04 '26	Buy	18.00	55,555	999,990	1,318,983	Feb 06 07:37 PM
FRAZIER KENNETH C	Director	Feb 04 '26	Buy	18.00	111,111	1,999,998	111,111	Feb 06 06:33 PM
Wolfe Josh	Director	Feb 04 '26	Buy	18.00	277,776	4,999,968	138,888	Feb 06 06:27 PM
Lux Venture Partners V, LLC	10% Owner	Feb 04 '26	Buy	18.00	277,776	4,999,968	138,888	Feb 06 06:25 PM

Eikon Therapeutics is a biopharmaceutical company. It engages in the development of medicines for unmet medical needs. The company was founded in 2019 and is headquartered in Millbrae, CA.

Ph.D.Dr. Roger M. Perlmutter M.D.

Chief Operating OfficerMr. Michael A. Klobuchar

M.D.Dr. Roy D. Baynes FACP

Co-Founder & Member of Scientific Advisory BoardDr. Robert Tjian Ph.D.

Co-Founder & Member of Scientific Advisory BoardDr. Eric Betzig Ph.D.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

EIKN

Eikon Therapeutics Inc

Upgrade your Finviz experience